Anna L. Blobaum

3.4k total citations
97 papers, 2.6k citations indexed

About

Anna L. Blobaum is a scholar working on Molecular Biology, Cellular and Molecular Neuroscience and Pharmacology. According to data from OpenAlex, Anna L. Blobaum has authored 97 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 69 papers in Molecular Biology, 57 papers in Cellular and Molecular Neuroscience and 14 papers in Pharmacology. Recurrent topics in Anna L. Blobaum's work include Neuroscience and Neuropharmacology Research (55 papers), Receptor Mechanisms and Signaling (42 papers) and Pharmacological Receptor Mechanisms and Effects (20 papers). Anna L. Blobaum is often cited by papers focused on Neuroscience and Neuropharmacology Research (55 papers), Receptor Mechanisms and Signaling (42 papers) and Pharmacological Receptor Mechanisms and Effects (20 papers). Anna L. Blobaum collaborates with scholars based in United States, Germany and France. Anna L. Blobaum's co-authors include Lawrence J. Marnett, Craig W. Lindsley, P. Jeffrey Conn, Colleen M. Niswender, Carrie K. Jones, J. Scott Daniels, Corey R. Hopkins, Alice L. Rodriguez, Darren W. Engers and Brenda C. Crews and has published in prestigious journals such as Journal of Biological Chemistry, Biochemistry and Cancer Research.

In The Last Decade

Anna L. Blobaum

97 papers receiving 2.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Anna L. Blobaum United States	29	1.2k	888	691	579	217	97	2.6k
Philip R. Kym United States	32	1.5k 1.2×	428 0.5×	566 0.8×	292 0.5×	97 0.4×	71	3.5k
Young‐Ger Suh South Korea	31	1.6k 1.3×	374 0.4×	1.4k 2.0×	535 0.9×	168 0.8×	207	4.3k
František Hubálek Denmark	28	1.7k 1.4×	415 0.5×	868 1.3×	490 0.8×	92 0.4×	55	3.3k
Boris Schmidt Germany	35	1.6k 1.3×	550 0.6×	843 1.2×	532 0.9×	76 0.4×	136	3.9k
Alessio Lodola Italy	38	1.8k 1.5×	864 1.0×	845 1.2×	1.3k 2.2×	143 0.7×	129	3.8k
Werner J. Geldenhuys United States	30	1.2k 1.0×	363 0.4×	489 0.7×	307 0.5×	76 0.4×	124	2.7k
Albert J. Robichaud United States	29	1.1k 0.9×	742 0.8×	1.1k 1.7×	570 1.0×	165 0.8×	74	2.8k
Marián Castro Spain	25	1.8k 1.5×	926 1.0×	347 0.5×	292 0.5×	73 0.3×	73	2.5k
James E. Audia United States	24	1.6k 1.3×	432 0.5×	561 0.8×	337 0.6×	69 0.3×	64	3.1k
Micah J. Niphakis United States	30	1.3k 1.1×	490 0.6×	944 1.4×	1.1k 1.8×	53 0.2×	57	3.1k

Countries citing papers authored by Anna L. Blobaum

Since Specialization

Citations

This map shows the geographic impact of Anna L. Blobaum's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna L. Blobaum with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna L. Blobaum more than expected).

Fields of papers citing papers by Anna L. Blobaum

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna L. Blobaum. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna L. Blobaum. The network helps show where Anna L. Blobaum may publish in the future.

Co-authorship network of co-authors of Anna L. Blobaum

This figure shows the co-authorship network connecting the top 25 collaborators of Anna L. Blobaum. A scholar is included among the top collaborators of Anna L. Blobaum based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna L. Blobaum. Anna L. Blobaum is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Engers, Julie L., Aaron M. Bender, Jonathan W. Dickerson, et al.. (2024). Discovery of VU6007496: Challenges in the Development of an M₁ Positive Allosteric Modulator Backup Candidate. ACS Chemical Neuroscience. 15(18). 3421–3433. 3 indexed citations

Spearing, Paul K., Hyekyung P. Cho, Vincent B. Luscombe, et al.. (2021). Discovery of a novel class of heteroaryl-pyrrolidinones as positive allosteric modulators of the muscarinic acetylcholine receptor M1. Bioorganic & Medicinal Chemistry Letters. 47. 128193–128193. 3 indexed citations

Rook, Jerri M., Hyekyung P. Cho, Pedro M. García-Barrantes, et al.. (2018). A Novel M ₁ PAM VU0486846 Exerts Efficacy in Cognition Models without Displaying Agonist Activity or Cholinergic Toxicity. ACS Chemical Neuroscience. 9(9). 2274–2285. 45 indexed citations

Yohn, Samantha E., Daniel J. Foster, Dan P. Covey, et al.. (2018). Activation of the mGlu1 metabotropic glutamate receptor has antipsychotic-like effects and is required for efficacy of M4 muscarinic receptor allosteric modulators. Molecular Psychiatry. 25(11). 2786–2799. 39 indexed citations

Felts, Andrew S., Alice L. Rodriguez, Ryan D. Morrison, et al.. (2018). Discovery of 4-alkoxy-6-methylpicolinamide negative allosteric modulators of metabotropic glutamate receptor subtype 5. Bioorganic & Medicinal Chemistry Letters. 29(1). 47–50. 4 indexed citations

Engers, Julie L., Elizabeth S. Childress, Vincent B. Luscombe, et al.. (2018). VU6007477, a Novel M₁ PAM Based on a Pyrrolo[2,3-b]pyridine Carboxamide Core Devoid of Cholinergic Adverse Events. ACS Medicinal Chemistry Letters. 9(9). 917–922. 13 indexed citations

Gogliotti, Rocco G., Nicole M. Fisher, J. Paige Adams, et al.. (2017). mGlu ₇ potentiation rescues cognitive, social, and respiratory phenotypes in a mouse model of Rett syndrome. Science Translational Medicine. 9(403). 63 indexed citations

Nance, Kellie D., Emily Days, C. David Weaver, et al.. (2017). Discovery of a Novel Series of Orally Bioavailable and CNS Penetrant Glucagon-like Peptide-1 Receptor (GLP-1R) Noncompetitive Antagonists Based on a 1,3-Disubstituted-7-aryl-5,5-bis(trifluoromethyl)-5,8-dihydropyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione Core. Journal of Medicinal Chemistry. 60(4). 1611–1616. 8 indexed citations

Temple, Kayla J., et al.. (2016). Synthesis and characterization of a series of chiral alkoxymethyl morpholine analogs as dopamine receptor 4 (D4R) antagonists. Bioorganic & Medicinal Chemistry Letters. 26(10). 2481–2488. 21 indexed citations

10.

García-Barrantes, Pedro M., Hyekyung P. Cho, Anna L. Blobaum, et al.. (2016). Re-exploration of the mGlu1 PAM Ro 07-11401 scaffold: Discovery of analogs with improved CNS penetration despite steep SAR. Bioorganic & Medicinal Chemistry Letters. 26(9). 2289–2292. 6 indexed citations

11.

Engers, Darren W., Anna L. Blobaum, Rocco D. Gogliotti, et al.. (2016). Discovery, Synthesis, and Preclinical Characterization ofN-(3-Chloro-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-3-amine (VU0418506), a Novel Positive Allosteric Modulator of the Metabotropic Glutamate Receptor 4 (mGlu₄). ACS Chemical Neuroscience. 7(9). 1192–1200. 39 indexed citations

12.

Swale, Daniel R., H. Kurata, Sujay V. Kharade, et al.. (2016). ML418: The First Selective, Sub-Micromolar Pore Blocker of Kir7.1 Potassium Channels. ACS Chemical Neuroscience. 7(7). 1013–1023. 26 indexed citations

13.

Rook, Jerri M., Masahito Abe, Hyekyung P. Cho, et al.. (2016). Diverse Effects on M₁ Signaling and Adverse Effect Liability within a Series of M₁ Ago-PAMs. ACS Chemical Neuroscience. 8(4). 866–883. 41 indexed citations

14.

Manka, Jason, Alice L. Rodriguez, Ryan D. Morrison, et al.. (2013). Octahydropyrrolo[3,4-c]pyrrole negative allosteric modulators of mGlu1. Bioorganic & Medicinal Chemistry Letters. 23(18). 5091–5096. 9 indexed citations

15.

Sheffler, Douglas J., Cody J. Wenthur, J. Scott Daniels, et al.. (2013). Development of the First Selective mGlu3 NAM from an mGlu5 PAM Hit. Europe PMC (PubMed Central). 3 indexed citations

16.

Felts, Andrew S., Alice L. Rodriguez, Ryan D. Morrison, et al.. (2013). Discovery of VU0409106: A negative allosteric modulator of mGlu5 with activity in a mouse model of anxiety. Bioorganic & Medicinal Chemistry Letters. 23(21). 5779–5785. 27 indexed citations

17.

Melancon, Bruce J., Thomas M. Bridges, Paige N. Vinson, et al.. (2012). Discovery of a selective M4 positive allosteric modulator based on the 3-amino-thieno[2,3-b]pyridine-2-carboxamide scaffold: Development of ML253, a potent and brain penetrant compound that is active in a preclinical model of schizophrenia. Bioorganic & Medicinal Chemistry Letters. 23(1). 346–350. 31 indexed citations

18.

Liedtke, Andy J., Brenda C. Crews, Anna L. Blobaum, et al.. (2012). Cyclooxygenase-1-Selective Inhibitors Based on the (E)-2′-Des-methyl-sulindac Sulfide Scaffold. Journal of Medicinal Chemistry. 55(5). 2287–2300. 64 indexed citations

19.

Uddin, Md. Jashim, Brenda C. Crews, Anna L. Blobaum, et al.. (2010). Selective Visualization of Cyclooxygenase-2 in Inflammation and Cancer by Targeted Fluorescent Imaging Agents. Cancer Research. 70(9). 3618–3627. 151 indexed citations

20.

Blobaum, Anna L.. (2005). MECHANISM-BASED INACTIVATION AND REVERSIBILITY: IS THERE A NEW TREND IN THE INACTIVATION OF CYTOCHROME P450 ENZYMES?. Drug Metabolism and Disposition. 34(1). 1–7. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact